Cargando…
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
The human epidermal growth factor receptor 3 (HER3) has in recent years been recognized as a key node in the complex signaling network of many different cancers. It is implicated in de novo and acquired resistance against therapies targeting other growth factor receptors, e.g., EGFR, HER2, and it is...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058629/ https://www.ncbi.nlm.nih.gov/pubmed/27532938 http://dx.doi.org/10.1080/19420862.2016.1212147 |